Subject Line
Discover the new comparative study
Have you read the latest comparative MWA publication?
In their Comparative Study of Ablation Zone of Emprint™ HP Microwave Device with Contemporary 2.4 GHz Microwave Devices in an Ex Vivo Porcine Liver Model, Dr. Terrence Hui et al. compare the ablation zones of four commercially available MWA manufacturers: Emprint™ HP, ECO, NeuWave™, and Solero.
View the study
The findings demonstrated that the new-generation Emprint™ HP system:
Created the desired large ablation zones*1
Produced the most spherical ablation zones*, achieving even ablative margins and potentially minimizing non-target tissue damage1
Potentially reduced the risk of complexities by using a single antenna1
Request a demo
Best regards,
The Medtronic Endoscopy Team
* At maximum system settings.
  1. Terrence C.H. Hui, Guo Yuan How, Michelle S.M. Chim and Uei Pua - Comparative Study of Ablation Zone of EMPRINT HP Microwave Device with Contemporary 2.4 GHz Microwave Devices in an Ex Vivo Porcine Liver Model
The Emprint™ ablation system is intended for use in percutaneous, laparoscopic and intraoperative coagulation (ablation) of soft tissue, such as lung, kidney and liver, including partial or complete ablation of non-resectable liver tumors. Contraindications: Microwave ablation procedures are not recommended for patients with cardiac pacemaker or other implanted electronic devices. Potential risks have not been evaluated. Microwave ablation procedures are not recommended for pregnant patients. Potential risks to the patient and/or fetus have not been established. Risks include but are not limited to tissue irritation or injury, infection and death. Microwave ablation procedures are not recommended for pregnant patients or those with cardiac pacemakers or other implanted electronic devices. Thermal injury, electric shock and explosion and fire hazards are possible. Please review the additional warning and precautions in the User’s Guide prior to use. Risks: While every attempt has been made to reduce patient and user risks, all surgeries using this device carry some residual risk, even when used by trained physicians. Residual risks include: foreign body in patient, foreign body reaction, additional needle stick or puncture delay of treatment, post ablation syndrome, pain, fever, malaise, nausea, vomiting, myalgia, inflammation, hemorrhage, hemoptysis, hematoma, infection, peritonitis, abscess, ascites, seroma, wound dehiscence, adhesions, ischemia, necrosis, urinary retention, emphysema, pleural effusion, pneumothorax, pulmonary or upper respiratory fistula, hemothorax, dyspnea, biliary stenosis, biliary obstruction, biloma, cholangitis, biliary cirrhosis, haemobilia, gastrointestinal fistula, liver dysfunction, hepatic insufficiency, hepatic infarction, jaundice, colonic perforation, renal fistula, embolism, death, atrial fibrillation, tachycardia, cardiomyopathy, arteriovenous fistula and cancer seeding. Important: Always refer to the Instructions For Use (IFU) packaged with the product for complete instructions, indications, contraindications, warnings and precautions.
© 2024 Medtronic. Medtronic, Medtronic logo and Engineering the Extraordinary are trademarks of Medtronic. TM* Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company